Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice

Journal of Diabetes

Volumn 6, Issue 3, 2014, Pages 243-250

  Ross, Stuart ^a,k   Dzida, Grzegorz ^b,k   Ji, Qiuhe ^c,k   Kaiser, Marcel ^e,k   Ligthelm, Robert ^f,k   Meneghini, Luigi ^g,k   Nazeri, Avideh ^h   Orozco Beltran, Domingo ^j,k   Pan, Changyu ^d   Svendsen, Anne Louise ⁱ   Yale, Jean François ^k   Pan, Chang Yu ^k   Liebl, Andreas ^k   Karnieli, Eddy ^k   Caputo, Salvatore ^k   Maran, Alberto ^k   Raimundo, Luisa ^k   Artola, Sara ^k   Damci, Taner ^k   Imamoglu, Sazi ^k   Vora, Jiten ^k   Khunti, Kamlesh ^k   more..

^a UNIVERSITY OF CALGARY   (Canada)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e Practice for Internal Medicine and Diabetology   (Germany)

^f EHM Clinic   (Netherlands)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h Global Medical Affairs   (Denmark)

ⁱ NOVO NORDISK A S   (Denmark)

^j MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^k NONE

more..

Author keywords

Ambulatory care; Basal insulin; Oral hypoglycemic agent; Sulfonylurea; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLINIDE DERIVATIVE; HEMOGLOBIN A1C; INSULIN DETEMIR; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; LONG ACTING INSULIN;

ADULT; ARTICLE; BODY MASS; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DRUG DOSE TITRATION; DRUG SAFETY; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MULTICENTER STUDY; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OPEN STUDY; PRE INSULIN HYPOGLYCEMIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEVERE HYPOGLYCEMIA; AGED; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; REGRESSION ANALYSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84898602320     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12091     Document Type: Article

References (27)

1. Peyrot M, Rubin RR, Lauritzen T etal. Resistance to insulin therapy among patients and providers: Results of the cross-national diabetes attitudes, wishes and needs (DAWN) study. Diabetes Care. 2005; 28: 2673-2679.
2. Stargardt T, Gonder-Frederick L, Krobot KJ, Alexander CM. Fear of hypoglycaemia: Defining a minimum clinically important difference in patients with type 2 diabetes. Health Qual Life Outcomes. 2009; 7: 91.
3. Hayes RP, Fitzgerald JT, Jacober SJ. Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. Int J Clin Pract. 2008; 62: 860-868.
4. Conthe P, Mata M, Orozco D etal. Degree of control and delayed intensification of antihyperglycaemic treatment in type 2 diabetes mellitus patients in primary care in Spain. Diabetes Res Clin Pract. 2011; 91: 108-114.
5. Murata GH, Duckworth WC, Shah JH, Wendel CS, Mohler MJ, Hoffman RM. Hypoglycemia in stable, insulin-treated veterans with type 2 diabetes: A prospective study of 1662 episodes. J Diabetes Complications. 2005; 19: 10-17.
6. Engler B, Koehler C, Hoffmann C etal. Relationship between HbA1c on target, risk of silent hypoglycemia and glycemic variability in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2011; 119: 59-61.
7. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: Pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005; 28: 2948-2961.
8. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: A study based on continuous monitoring. Diabetes Care. 2003; 26: 1485-1489.
9. Gerstein HC, Miller ME, Genuth S etal. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011; 364: 818-828.
10. Bonds DE, Miller ME, Bergenstal RM etal. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: Retrospective epidemiological analysis of the ACCORD study. BMJ. 2010; 340: b4909.
11. Miller ME, Bonds DE, Gerstein HC etal. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: Post hoc epidemiological analysis of the ACCORD study. BMJ. 2010; 340: b5444.
12. Zoungas S, Patel A, Chalmers J etal. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010; 363: 1410-1418.
13. Khunti K, Damci T, Meneghini L, Pan CY, Yale JF. Study of Once Daily Levemir (SOLVE): Insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes Obes Metab. 2012; 14: 654-661.
14. Khunti K, Caputo S, Damci T etal. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Diabetes Obes Metab. 2012; 14: 1129-1136.
15. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35: 1364-1379.
16. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: A meta-analysis. Diabetes Res Clin Pract. 2008; 81: 184-189.
17. Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ. Optimal insulin regimens in type 2 diabetes mellitus: Systematic review and meta-analyses. Diabetologia. 2009; 52: 1990-2000.
18. Blonde L, Merilainen M, Karwe V, Raskin P. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: An assessment of two different fasting plasma glucose targets: The TITRATE study. Diabetes Obes Metab. 2009; 11: 623-631.
19. Holman RR, Thorne KI, Farmer AJ etal. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007; 357: 1716-1730.
20. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008; 51: 408-416.
21. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26: 3080-3086.
22. Meneghini LF, Dornhorst A, Sreenan S. Once-daily insulin detemir in a cohort of insulin-naive patients with type 2 diabetes: A sub-analysis from the PREDICTIVE study. Curr Med Res Opin. 2009; 25: 1029-1035.
23. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006; 28: 1569-1581.
24. Gerstein HC, Miller ME, Byington RP etal. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-2559.
25. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: A nested case-control analysis. Diabetes Care. 2008; 31: 2086-2091.
26. Caputo S, Andersen H, Kaiser M etal. Effect of baseline glycosylated hemoglobin a1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice. Endocr Pract. 2013; 19: 462-470.
27. Janssen MM, Snoek FJ, Heine RJ. Assessing impaired hypoglycemia awareness in type 1 diabetes: Agreement of self-report but not of field study data with the autonomic symptom threshold during experimental hypoglycemia. Diabetes Care. 2000; 23: 529-532.